Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

, Shire will present the highlights of new data from an exploratory study for VYVANSE as adjunctive therapy in adults with significant cognitive impairments with partially or fully remitted MDD. This study met its primary and secondary endpoints.


 

  • A Phase 3 clinical trial program to assess the efficacy and safety of VYVANSE as adjunctive therapy in patients with MDD has been initiated.

BOARD CHANGES

Mr Patrick Langlois, who has been a member of Shire's Board of Directors for 6 years, will be stepping down from the Board and from the Company's Audit, Compliance & Risk Committee and its Remuneration Committee on the expiry of his current term of office on November 10, 2011. Matthew Emmens, Chairman of Shire, said "We thank Patrick for his contribution to Shire over the past few years".

ADDITIONAL INFORMATION

The following additional information is included in this press release:

Page Overview of Third Quarter 2011 Financial Results 6 Financial Information 10 Non GAAP Reconciliations 19 Safe Harbor Statement 23 Explanation of Non GAAP Measures 24 Trademarks 25

OVERVIEW OF THIRD QUARTER 2011 FINANCIAL RESULTS

1.    Product sales

For the three months to September 30, 2011 product sales increased by 28% to $1,018.4 million (Q3 2010: $794.3 million) and represented 94% of total revenues (Q3 2010: 91%).

Product Highlights

US Exit Market Year on year growth Share(1) Sales $M Sales CER US Rx(1) Product VYVANSE 199.7 +32% +32% +20% 16% ADDERALL XR 149.9 +50% +50% +8% 7% REPLAGAL 129.0 +40% +31% n/a(3) n/a(3) ELAPRASE(R) 109.6 +13% +7% n/a(2) n/a(2) LIALDA/MEZAVANT(R) 89.7 +18% +17% +7% 21% VPRIV 64.6 +31% +27% n/a(2) n/a(2) INTUNIV(R) 56.1 +50% +50% +59% 4% PENTASA(R) 55.9 -2% -2% -4% 15% DERMAGRAFT 50.0 n/a n/a n/a(2) n/a(2) FOSRENOL(R) 40.5 -10% -14% -17% 5% FIRAZYR 7.2 +148% +129% n/a(2) n/a(2) RESOL
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... NEW YORK , Aug. ... announces that a new market ... its catalogue: Whole ... (Systems, Kits (Library Preparation, Target ... Technology (Sequencing by Synthesis), by ...
(Date:8/28/2014)... SunTrust Robinson Humphrey (STRH) today announced the ... research team in biotechnology and oilfield services.  ... demonstrates our commitment to providing our valued institutional ... decision making," said Biff Woodruff , Head ... significant investments in differentiated content at a time ...
(Date:8/28/2014)... by a Florida State University research team has led ... temperature, emit white light, and convert photon energy directly ... a butterfly. , Biwu Ma, associate professor in the ... College of Engineering, created the molecule in a lab ... that his creation has many other unique capabilities. , ...
(Date:8/28/2014)... Earlier this month, a report was created by ... Air Force on the performance of vehicles using an ... of fuel made from mustard seeds, offered great potential ... Eco friendly future. In fact, every branch of the ... of foreign oil over the next few years. They ...
Breaking Biology Technology:Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... 2011 PharmaVentures today announced the launch of ... Essential Deal Trends: Oncology 2011 . This new series ... and commercialising new drugs. The first report in the series ... active deal making therapeutic area in the pharmaceutical and biotechnology ...
... timing procedures don,t accurately detect false starts by female sprinters, ... Under the current rules, a woman can purposely ... of a second, without getting called for a false start, ... women in the race because a medal can be won ...
... 19, 2011 Physicians and scientists from Reproductive ... the results of their groundbreaking research study entitled ... Reproductive Potential While Blastocyst Biopsy Does Not: A ... Sibling Embryos.   The study, led by Richard ...
Cached Biology Technology:Pfizer, Sanofi and Genentech Feature Prominently in the Oncology Edition of PharmaDeals' New Publication Series; Essential Deal Trends 2Pfizer, Sanofi and Genentech Feature Prominently in the Oncology Edition of PharmaDeals' New Publication Series; Essential Deal Trends 3False starts can sneak by in women's sprinting 2False starts can sneak by in women's sprinting 3Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 2Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 3
(Date:9/1/2014)... About 50 years ago, electron microscopy revealed the ... move around and disappear. But scientists still don,t know ... collections of proteins are believed to be crucial to ... a new approach to disease treatment., In the ... a call to investigators from various backgrounds, from biophysics ...
(Date:8/31/2014)... bacteria C. diff , that causes diarrhoea, temperature ... at the University of Leicester. , Using a mass ... possible to identify the unique ,smell, of C. ... the condition., What is more, the Leicester team say ... the disease simply from their smell a chemical ...
(Date:8/31/2014)... the past several decades, malaria diagnosis has changed very little. ... smears the blood across a glass slide, stains it with ... Plasmodium parasite, which causes the disease. This approach gives an ... an important measure of disease severity but is ... A research team from the Singapore-MIT Alliance for Research and ...
Breaking Biology News(10 mins):Scientists call for investigation of mysterious cloud-like collections in cells 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2A new way to diagnose malaria 2A new way to diagnose malaria 3
... Boston, MA - Tiny particles only billionths of a meter ... human haircould offer big hope in a small package to the ... everything from jewelry to coins and cell phones, say scientists at ... issue of Nature Nanotechnology, the team will report a ...
... the largest study of its kind, researchers from a consortium ... linked to late-onset Alzheimer,s disease. Each of these genes adds ... the disease, and together they offer a portal into the ... to determine who is at risk of developing the disease, ...
... Medicine researchers are part of a consortium that has identified ... a person developing Alzheimer,s disease later in life. The ... The consortium also contributed to the identification of a ... United States and Europe. "Mount Sinai has unique resources ...
Cached Biology News:Nanoparticles offer hope for common skin allergy 2Nanoparticles offer hope for common skin allergy 3Alzheimer’s disease consortium identifies four new genes for Alzheimer’s disease risk 2Alzheimer’s disease consortium identifies four new genes for Alzheimer’s disease risk 34 new genes identified for Alzheimer's disease risk 2
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Biology Products: